Trevi Therapeutics (NASDAQ:TRVI) Given New $20.00 Price Target at Oppenheimer

Trevi Therapeutics (NASDAQ:TRVI) had its price objective increased by stock analysts at Oppenheimer from $12.00 to $20.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 235.80% from the company’s current price.

A number of other equities analysts have also recently commented on TRVI. Needham & Company LLC lifted their price target on Trevi Therapeutics from $8.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $9.00 to $29.00 in a research note on Monday. HC Wainwright raised their price target on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the stock a “buy” rating in a report on Monday. Finally, D. Boral Capital reiterated a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a report on Friday. Seven investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $15.94.

Trevi Therapeutics Trading Down 1.9 %

Shares of NASDAQ:TRVI traded down $0.11 on Tuesday, reaching $5.96. 643,761 shares of the company traded hands, compared to its average volume of 1,955,648. The stock has a market capitalization of $457.81 million, a P/E ratio of -13.52 and a beta of 0.90. The business’s 50-day simple moving average is $4.18 and its 200 day simple moving average is $3.54. Trevi Therapeutics has a 52 week low of $2.30 and a 52 week high of $7.39.

Institutional Trading of Trevi Therapeutics

Several large investors have recently modified their holdings of the company. Summit Investment Advisors Inc. grew its stake in shares of Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after purchasing an additional 2,894 shares during the period. Bank of New York Mellon Corp grew its position in shares of Trevi Therapeutics by 2.1% during the 4th quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock valued at $578,000 after acquiring an additional 2,935 shares during the period. SG Americas Securities LLC increased its position in Trevi Therapeutics by 14.5% in the fourth quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock worth $110,000 after buying an additional 3,387 shares in the last quarter. Invesco Ltd. raised its stake in Trevi Therapeutics by 21.2% during the 4th quarter. Invesco Ltd. now owns 23,621 shares of the company’s stock worth $97,000 after acquiring an additional 4,133 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Trevi Therapeutics by 32.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 25,166 shares of the company’s stock valued at $104,000 after buying an additional 6,119 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.